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Hemorrhage is a typical pathological feature of leptospirosis. Binding of vonWillebrand factor (vWF) to platelet
glycoprotein-Ibα (GPIbα) is a crucial step in initiation of platelet aggregation. The products of L. interrogans vwa-I
and vwa-II genes contain vWF-A domains, but their ability to induce hemorrhage has not been determined.
Methods: Human (Hu)-platelet- and Hu-GPIbα-binding abilities of the recombinant proteins expressed by
L. interrogans strain Lai vwa-I and vwa-II genes (rLep-vWA-I and rLep-vWA-II) were detected by flowcytometry,
surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC). Hu-platelet aggregation and its sig-
naling kinases and active components were detected by lumiaggregometry, Western analysis, spectrophotome-
try and confocal microscopy. Hu-GPIbα-binding sites in rLep-vWA-I and rLep-vWA-II were identified by SPR/ITC
measurements.
Findings: Both rLep-vWA-I and rLep-vWA-II were able to bind to Hu-platelets and inhibit rHu-vWF/ristocetin-in-
duced Hu-platelet aggregation, but Hu-GPIbα-IgG, rLep-vWA-I-IgG and rLep-vWA-II-IgG blocked this binding or
inhibition. SPR and ITC revealed a tight interaction between Hu-GPIbα and rLep-vWA-I/rLep-vWA-II with KD
values of 3.87 × 10−7-8.65 × 10−8 M. Hu-GPIbα-binding of rL-vWA-I/rL-vWA-II neither activated the PI3K/
AKT-ERK and PLC/PKC kinases nor affected the NO, cGMP, ADP, Ca2+ and TXA2 levels in Hu-platelets. G13/R36/
G47 in Lep-vWA-I and G76/Q126 in Lep-vWA-II were confirmed as the Hu-GPIbα-binding sites. Injection of
rLep-vWA-I or rLep-vWA-II in mice resulted in diffuse pulmonary and focal renal hemorrhage but this hemor-
rhage was blocked by rLep-vWA-I-IgG or rLep-vWA-II-IgG.
Interpretation: The products of L. interrogans vwa-I and vwa-II genes induce hemorrhage by competitive inhibi-
tion of vWF-mediated Hu-platelet aggregation.icrob
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s an open access article under1. Introduction
Leptospirosis caused by Leptospira is a common global zoonotic in-
fectious disease [1,2]. The disease is endemic in Asia, Oceania and
South America, but in recent years it has been considered as an emerg-
ing infectious disease in Europe, North America and Africa, due to fre-
quent case reports and several outbreaks [3–10].
Many animals such as rats and livestock serve as the natural hosts of
pathogenic Leptospira genospecies and can persistently shed the spiro-
chetes from their urine for a longperiod of time [11]. Human individualsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Leptospira interrogans is themost common causative agent of lep-
tospirosis, a worldwide zoonotic infectious disease. Hemorrhage
is a typical pathological feature and common lethal cause of lepto-
spirosis, but its pathogenesis remains unknown. von Willebrand
factor (vWF) triggers the platelet-mediated blood coagulation in
humans and mammalian animals by binding platelets with its re-
gion A (vWF-A). The LB054 (vwa-I) and LB055 (vwa-II) genes of
L. interrogans strain Lai contain vWF-A superfamily domains, but
no reports have addressed their possible role in hemorrhage of
leptospirosis.
Added value of this study
Our study demonstrated that the recombinant products of the
vwa-I and vwa-II genes (rLep-vWA-I and rLep-vWA-II) are able to
bind human or mouse platelets but block the vWF/ristocetin-
mediated human platelet aggregation in vitro in which the platelet
aggregation-associated PI3K/AKT-ERK and PLCγ2/PKC signaling
pathways are not activated. Moreover, rLep-vWA-I and rLep-
vWA-II presented a high-affinity binding ability with
glycoprotein-Ibα, the vWF receptor on platelets to initiate platelet
aggregation and the G13/R36/G47 in Lep-vWA-I and G76/Q126
in Lep-vWA-II acted as the Hu-GPIbα-binding sites. rLep-vWA-I
and rLep-vWA-II caused the diffuse pulmonary and focal renal
hemorrhage inmice aswell as the dysfunction of animal peripheral
blood coagulation.
Implications of all the available evidence
The products of the L. interrogans vwa-I and vwa-II genes are the
inducers of hemorrhage by competitive inhibition of vWF-
mediated platelet aggregation in blood coagulation.
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wet soil. After invading into the human body through the skin and mu-
cosa, pathogenic Leptospira genospecies can promptly enter the blood-
stream to cause toxic septicemia and then spread into internal organs
and tissues such as lungs, liver and kidneys to cause tissue injury
[11,12].
Except for non-specific common symptoms such as high fever, head-
ache and myalgia, severe leptospirosis patients are characterized by
hemorrhage and jaundice and can die of septic shock, pulmonary diffuse
hemorrhage (PDH) and acute renal failure [13,14]. In particular, PDH
has a high mortality that usually causes rapid death of leptospirosis pa-
tients following frank hemoptysis and mouth-nose bleeding due to ex-
tensive intra-alveolar and interstitial hemorrhage [13–15].
Histopathological examination has confirmed that the hemorrhage in
leptospirosis is diapedetic through small blood vessels, which occurs
in nearly all tissues of the patients [15]. However, the molecular basis
and mechanism of hemorrhage during leptospirosis remain unknown.
The blood coagulation system has an important physiological func-
tion to prevent hemorrhage [16]. In the blood coagulation process,
platelet aggregation plays a crucial role by providing a platform for in-
teraction and activation of blood coagulation factors and von
Willebrand factor (vWF) initiates the platelet aggregation by binding
to glycoprotein-Ib-α in the GPIb-IX-V complex in platelet membrane
[17]. vWF contains twelve regions designated D'-D3-A1/2/3-D4-B1/2/
3-C1/2-CK, of which the A1-A3 regions contain GPIbα-binding domains
[18]. After ligation of vWF with GPIb-IX-V, the PI3K/AKT-ERK and PLC/PKC signaling pathways in platelets are activated by phosphorylation
to cause an increase in NO, cGMP and free Ca2+ levels, which promote
synthesis of thromboxane A2 (TXA2) and release of ADP from granules
in platelets. High levels of TXA2 and ADP induce talin and αIIbβ3
integrin polymerization to cause platelet aggregation [17–19]. There-
fore, vWF is a key factor in human blood coagulation.
Among pathogenic Leptospira genospecies, Leptospira interrogans is
the most predominant global genospecies [1,13]. L. interrogans has
many serogroups and serovars but L. interrogans serogroup
Icterohaemorrhagiae serovar Lai is responsible for disease in over 60%
of leptospirosis patients in China [3,14,20]. In the genomic DNA of
L. interrogans serovar Lai strain Lai, we found that LB054 and LB055
genes contain several vWF type-A (vWF-A) superfamily domains and
the two geneswere namedas vwa-I and vwa-II [21]. Previous studies re-
ported that the vWF-A peptide segment from human vWF can bind to
the GPIbα of human platelets, but it does not evoke platelet functional
responses and result in blockage of vWF-induced platelet aggregation
[22,23]. Therefore, we hypothesized that the products of L. interrogans
vwa-I and vwa-II genes may induce hemorrhage in leptospirosis by
competitive inhibition of vWF binding to GPIbα which blocks platelet
aggregation.
In the present study, we therefore investigated the distribution of
vwa-I and vwa-II genes in different pathogenic or saprophytic Leptospira
strains. Subsequently, the platelet GPIbα-binding and aggregation-
inhibiting ability of L. interrogans serovar Lai strain Lai recombinant
vwa-I and vwa-II gene products containing vWF-A superfamily domains
(rLep-vWA-I and rLep-vWA-II), as well as the expression and secretion
of Lep-vWA-I and Lep-vWA-II of the spirochete during infection of
human vascular endothelial cells were determined. Moreover, rLep-
vWA-I- and rLep-vWA-II-induced hemorrhage inmicewas also demon-
strated. The results of this study identify the products of L. interrogans
vwa-I and vwa-II as hemorrhage inducers in leptospirosis by competi-
tive inhibition of vWF-mediated platelet aggregation.2. Materials and methods
2.1. Ethics statement
All subjects (peripheral blood samples from three volunteers in our
laboratory) gavewritten informed consent, and the studywas approved
by the Human Ethics Committee of Zhejiang University School of Med-
icine, and complied with the Declaration of Helsinki. Animal experi-
ments were performed in accordance with the National Regulations
for the Administration of Experimental Animals of China (1988–002)
and the National Guidelines for Experimental Animal Welfare of China
(2006–398). All the animal experimental protocols were approved by
the Ethics Committee for Animal Experiment of Zhejiang University
School of Medicine.2.2. Leptospiral strains and culture
Thirteen strains of pathogenic Leptospira belonging to three
genospecies for the serological diagnosis of human leptospirosis in
China and two strains of non-pathogenic saprophytic L. biflexa were
shown in Supplementary Data [3]. All the leptospiral strains were cul-
tured in EMJH liquid medium at 28 °C [20].2.3. Cell line and culture
Human umbilical vein endothelial cell (HUVEC) line was provided
by the Cell Bank of ChineseAcademyof Sciences. The cellswere cultured
in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS)
(Gibco, USA), 100 U/mL penicillin and 100 μg/mL streptomycin
(Sigma, USA) at 37 °C in an atmosphere of 5% CO2.
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Female C3H/HeJ mice (15 ± 1 g, three-weeks old), female C57BL/6
mice (18 ± 2 g, four weeks old) for generating Leptospira-infected ani-
mal model [24], and New Zealand rabbits (3.0–3.5 kg) for preparing
rLep-vWA-I-IgG and rLep-vWA-II-IgG were provided by the Laboratory
Animal Center of Zhejiang University.
2.5. Detection of vwa-I and vwa-II genes in leptospiral strains
Genomic DNAs from the fifteen leptospiral strains were extracted
using a Bacterial Genomic DNA Extraction Kit (Axygen, USA). The entire
LB054 (vwa\\I) or LB055 (vwa-II) gene was amplified from the DNA
templates by PCR with the primers vwa-I-1F/vwa-I-1R or vwa-II-1F/
vwa-II-1R (Table 1) using a High-Fidelity PCR Kit (TaKaRa, China). All
the PCR products were examined by 1.5% ethidium bromide pre-
stained agarose gel electrophoresis and then cloned into pMD19-T plas-
mid using a PCR Product T-A Cloning Kit (TaKaRa) for sequencing by
Invitrogen Co. at Shanghai in China. The sequence identities were ana-
lyzed and compared with those in GenBank using BLAST software.
2.6. Bioinformatic analysis of vwa-I and vwa-II genes
The structures and functional domains in the vwa-I and vwa-II genes
of L. interrogans serogroup Icterohaemorrhagiae serovar Lai strain Lai
were analyzed using TMHMM, PsortB, Octopus, SignalP-4.1 and NCBI-
Batch CD-Search softwares.
2.7. Expression of vwa-I and vwa-II gene segments
Expression of the vwa-I and vwa-II gene segments containing the en-
tire vWF-A superfamily domains (vwa-I528 and vwa-II603) from
L. interrogans serogroup Icterohaemorrhagiae serovar Lai strain Lai in
Escherichia coli and extraction of the expressed recombinant proteins
(rLep-vWA-I and rLep-vWA-II) were shown in Supplementary
Information.
2.8. Removal of lipopolysaccharide in rLep-vWA-I and rLep-vWA-II
Possible contaminated E. coli LPS in the rLep-vWA-I and rLep-vWA-II
extracts were removed with a Detoxi-gel endotoxin removing column
chromatography (Thermo Scientific, USA) using pyrogen-free water
for elution and then detected using a Limulus Amebocyte Lysate Test
Kit (Lonza, Switzerland) as previously described [24,25].Table 1
Information of primers used in this study.
Primer Sequence (5′ to 3′) Purpose Size
(bp)
vwa-I-1 F: ATGAATTTTCAATATCCTTAC Detection of emtire vwa-I
gene
939
R: TCATACATAATATCTCAGAAA
vwa-II-1 F: TTGATTTCTAAAATAAGGGAA Detection of entire vwa-II
gene
957
R: TCATATTACAGAAACGCATTTC
vwa-I-2 F: GCGCATATG(Nde I)GAAGGAGTA
GATATATTA
Expression of vwa-I528
segment
528
R: GCGCTCGAG(Xho I)CATTTCCTCCG
GATCTTC
vwa-II-2 F: GCGCATATG(Nde I)GATATACTCTT
TTTAGTG
Expression of vwa-II603
segment
603
R: GCGCTCGAG(Xho I)TTGTAGAAT
TGTAGAATC
vwa-I-3 F: TTGCAGGTGCGGCTTATT Detection of vwa-I-mRNA 111
R: CGATTGCGGTCCCTTGTT
vwa-II-3 F: TTCGTGGATTGGATGTGG Detection of
vwa-II-mRNA
161
R: GGAAATCGCTTGTGGATC
16S-RNA F: CTTTCGTGCCTCAGCGTCAGT Inner reference used in
qRT-PCRs
145
R: CGCAGCCTGCACTTGAAACTA
F: forward primer. R: reverse primer. Underlined areas indicate the sites of endonucleases.2.9. Preparation of rLep-vWA-I-IgG and rLep-vWA-II-IgG
The preparation of rabbit anti-rLep-vWA-I-IgG or rLep-vWA-II-IgG
was shown in Supplementary Data.
2.10. Preparation of human and mouse platelets
Peripheral blood samples from healthy volunteers and C3H/HeJ or
C57BL/6 mice were mixed with 0.1 volume of ACD buffer (75 mM so-
dium citrate, 39 mM citric acid, and 135 mM dextrose, pH 6.5) to pre-
vent pellet self-aggregation, and then diluted with 2 volumes of MTH
buffer (20 mM HEPES, 137 mM NaCl, 13.8 mM NaHCO3, 2.5 mM KCl,
0.36 mMNaH2PO4, 5.5 mM glucose, pH 7.4). The diluted blood samples
were centrifuged at 180 ×g for 10min at room temperature. The human
(Hu) ormouse (Ms) platelet rich plasmaswere suspended in ACDbuffer
and then centrifuged at 750×g for 15min at room temperature. TheHu-
platelets andMs-plateletswere suspended inMTHbuffer for immediate
use with no self-aggregation using a lumiaggregometer (type Model-
700, Chrono-Log, USA) [26].
2.11. Determination of Hu/Ms-platelet-binding ability of rLep-vWA-I and
rLep-vWA-II
Hu/Ms-platelet-binding ability of rLep-vWA-I or rLep-vWA-II was
determined by flow cytometry [27]. Briefly, the Hu/Ms-platelets (107)
were incubated with 2 μg rLep-vWA-I or rLep-vWA-II at 22 °C for 0.5,
1, 2 or 4 h, and then thoroughlywashedwith 0.01Mphosphate buffered
saline (PBS, pH 7.4). Using 1:200 diluted rabbit anti-rLep-vWA-I- or
rLep-vWA-II-IgG as the primary antibody and FITC-labeled goat anti-
rabbit-IgG (Abcam, USA) as the secondary antibody, the Hu/Ms-
platelet-binding percentages of rLep-vWA-I and rLep-vWA-II were de-
tected using a flow cytometer (type FC-500MCL, Beckman Coulter,
USA) with 485/538 nm excitation/emission wavelengths. In the detec-
tion, 10 μg rHu/rMs-vWF (Abcam) plus 150 μM ristocetin (Sigma), a
common cofactor of vWF for binding GPIbα to induce platelet aggrega-
tion in vitro [26,28], and rHlpA, a recombinant hemolysin of
L. interrrogans [24], were used as the controls.
2.12. Antibody blockage tests
Hu-platelets were incubated with rabbit rHu-GPIbα-IgG (Abcam) at
22 °C for 3 h while rLep-vWA-I or rLep-vWA-II was incubated with
rLep-vWA-I-IgG or rLep-vWA-II-IgG at 37 °C for 1 h. The percentages
of rLep-vWA-I or rLep-vWA-II binding to the GPIbα-blocked Hu-
platelets and the IgG-combined rLep-vWA-I or rLep-vWA-II binding to
Hu-platelets were detected by flow cytometry as above.
2.13. Determination of Hu-GPIbα-binding ability of rLep-vWA-I and rLep-
vWA-II
Hu-GPIbα-binding ability of rLep-vWA-I or rLep-vWA-II was deter-
mined by SPR and ITC [29,30]. For SPR detection, 1 nM rHu-GPIbα (R&D,
USA) was cross-linked on the activated CM5 sensing array (GE, USA)
and then 0.05–0.8 nM rLep-vWA-I or rLep-vWA-II in PBS flowed
through the surface of rHu-GPIbα-binding array. The combination of
rLep-vWA-I or rLep-vWA-II with rHu-GPIbα was detected using a
SPR-based detector (Type-T200, GE) and quantified by the values of
equilibrium association constant (KD). For ITC detection, 1 μM rLep-
vWA-I- or rLep-vWA-II in PBS was added in the titration pool while
0.1 μM rHu-GPIbα in PBS was added in the sample pool. The KD values
reflecting the combination of rLep-vWA-I or rLep-vWA-II with the
rHu-GPIbα in titrating process were detected using a type VP-ITC mi-
crocalorimeter (MicroCal, USA) and then analyzed using Origin soft-
ware. In the detection, rHlpA, a recombinant hemolysin of
L. interrrogans [24], was used as the negative array-linking fixed and
mobile phase controls in SPR and the negative titration control in ITC.
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The products of vwa-I and vwa-II genes in total leptospiral proteins
were pulled down with rHu-GPIbα (R&D) by co-precipitation assay.
Briefly, freshly-cultured L. interrogans strain Lai was precipitated by a
10,000 ×g centrifugation at 4 °C for 30 min. After washing twice with
PBS and centrifugation again, the leptospiral pellet was suspended in
distilled water and then ultrasonically broken on ice. The lysate was
centrifuged at 10,000 ×g for 10 min (4 °C) to remove leptospiral debris
and the supernatant containing total leptospiral proteins was collected
to detect protein concentration using a BCA Protein Assay Kit (Thermo
Scientific). 20 μg mouse anti-rHu-GPIbα-IgG (Abcam) in 500 μL PBS
was mixed with 100 μL of 6 mg/mL protein-A-coated agarose beads
(Millipore, USA) for incubation in a 90 rpm rotator (4 °C) overnight to
form protein-A-GPIbα-IgG beads. After a 10-min centrifugation at
14,000 ×g (4 °C) and washing with PBS, the beads were suspended in
500 μL PBS and then incubated with 20 μg rHu-GPIbα (R&D) as above
to form protein-A-GPIbα-IgG-GPIbα beads. After centrifugation and
washing with PBS as above, the beads were suspended in 500 μL PBS
and then incubatedwith 200 μg total leptospiral proteins in a 90 rpmro-
tator (4 °C) for 2 h. After centrifugation and washing thoroughly with
PBS, the beads were suspended in Laemmili SDS-PAGE sample buffer
for a 5-min water-bath at 100 °C to release protein-A-GPIbα-IgG-
binding proteins. After a 10-min centrifugation at 14,000 ×g (4 °C),
the supernatant was subjected to SDS-PAGE to examine the released
proteins.
2.15. Identification of rHu-GPIbα-binding leptospiral proteins
The released proteins from protein-A-GPIbα-IgG beads in co-
precipitation assay were identified by liquid chromatography plus a
type LC1000-LTQ tandem mass spectrometry (LC-MS/MS, Thermo Sci-
entific). The obtained data were automatically searched against the ge-
nomic database of L. interrogans strain Lai in GenBank (accession No.:
NC_004342.2) using Proteome Discoverer 1.4 software.
2.16. Platelet aggregation and inhibition tests
In the platelet aggregation test, 10 μg rHu-vWF plus 150 μM
ristocetin (rHu-vWF/ristocetin) were used as the inducers of Hu-
platelet aggregation in vitro [18,26]. Hu-platelets (108) were incubated
with 5 μg rLep-vWA-I or rLep-vWA-II in MTB at 37 °C for 1 h and then
the rHu-vWF/ristocetin-mediated rLep-vWA-I- or rLep-vWA-II-treated
Hu-platelet aggregation was detected using a lumiaggregometer (type
Model-700, Chrono-Log, USA). On the other hand, rLep-vWA-I or
rLep-vWA-II was pretreated with rLep-vWA-I-IgG or rLep-vWA-II-IgG
at 37 °C for 1 h and then the rLep-vWA-I-IgG or rLep-vWA-II-IgG to re-
verse the role of rLep-vWA-I or rLep-vWA-II on inhibition of rHu-vWF/
ristocetin-mediated Hu-platelet aggregation was detected as above.
2.17. Detection of signal kinase phosphorylation in platelet aggregation
Hu-platelets (108) were incubated with 5 μg rLep-vWA-I or rLep-
vWA-II in MTB at 37 °C for 1 h. The Hu-platelets were precipitated by
a 750 ×g centrifugation for 15 min at room temperature. After washing
thoroughly with PBS and centrifugation, the Hu-platelet pellets were
lysed with RIPA lysis buffer (Beyotime BioTech, China). The lysates
were centrifuged at 3000 ×g for 10 min to remove Hu-platelet debris.
The supernatants were collected to detect protein concentration using
a BCA Protein Assay Kit (Thermo Scientific) and then were submitted
to SDS-PAGE andelectro-transferring onto PVDFmembrane (Millipore).
The phosphorylation levels of PI3K/AKT, ERK, PLC and PKC were de-
tected byWestern Blot assay using AKT, ERK1/2, PLC and PKC Phosphor-
ylation Detection Kits (Cell Signaling, USA). In the assays, 10 μg rHu-
vWF plus 150 μM ristocetin (rHu-vWF/ristocetin)were used as the con-
trol [26,28].2.18. Measurement of nitric oxide, cGMP, TXA2 and ADP in platelets
Hu-platelets (108) were incubated with 5 μg rLep-vWA-I or rLep-
vWA-II in MTB at 37 °C for 1 h. The Hu-platelets were lysed and then
centrifuged as above. The OD540 or OD450 values reflecting the nitric
oxide (NO) or cGMP levels in the supernatants were measured using a
Griess's Diazotization NO Assay Kit (Promega, USA) or a cGMP Assay
Kit (R&D) by spectrophotometry. The supernatants were diluted at
1:50 with the assay buffer and then the OD450 values reflecting TXB2
levels were measured using a TXB2 Assay Kit (R&D) by spectrophotom-
etry. Besides, theHu-plateletswere precipitated as above for homogeni-
zation in the assay buffer and then centrifuged at 10,000 ×g for 10 min.
The supernatants were diluted with 50-fold volumes of the assay buffer
for detecting the released ADP at the OD570 using an ADP Assay Kit
(Abcam) by spectrophotometry. In the detection, 10 μg rHu-vWF plus
150 μM ristocetin (rHu-vWF/ristocetin) were used as the control
[26,28].
2.19. Measurement of free Ca2+ in platelets
Hu-platelets (108) were incubated with 5 μg rLep-vWA-I or rLep-
vWA-II in MTB at 37 °C for 1 h. The Hu-platelets were precipitated
and washed as above. The Hu-platelet pellets were suspended in the
assay buffer and then incubated with free Ca2+ Fluo-4 AM fluorescence
probe at 37 °C for 30min, followed by an additional incubation at room
temperature for 30min. Thefluorescence intensity (FI) values reflecting
free Ca2+ levels in the Hu-platelets using a Fluo-4 AM Calcium Assay Kit
(Molecular Probes, USA) by laser confocal microscopy (type LSM510,
Zeiss, Germany) with 494/516 nm excitation/emission wavelength. In
the detection, 10 μg rHu-vWF plus 150 μM ristocetin (rHu-vWF/
ristocetin) were used as the control [26,28].
2.20. Functional determination of products of vwa-I528 and vwa-II603
mutants
Previous studies confirmed that the point-mutation of some certain
amino acid residues at the GPIb-binding sites in vWF-A domains of vWF
caused the decrease of vWF-platelet combination and vWF-induced
platelet aggregation [31,32]. The generation of point-mutated vwa-I
and vwa-II gene segments containing entire vWF-A superfamily do-
mains (vwa-I528 and vwa-II603), the expression of vwa-I528 and
vwa-II603 segments in E. coli and the extraction of target recombinant
products were shown in Supplemental Information. The Hu-GPIbα-
binding and Hu-platelet aggregation-inhibiting abilities of point-
mutated rLep-vWA-I and rLep-vWA-II proteins were determined by
flow cytometry, SPR and ITC detection, and Hu-platelet aggregation in-
hibition test as described above.
2.21. Measurement of vwa-I and vwa-II mRNAs during infection of HUVEC
HUVEC (106 per well) was seeded in 6-well culture plates (Corning,
USA) for a pre-incubation in an atmosphere of 5% CO2 at 37 °C over-
night. Freshly-cultured L. interrogans strain Lai was centrifuged at
13,800 ×g for 15min at 15 °C and thenwashed twicewith PBS. The har-
vested leptospires were counted under a dark-field microscope with a
Petroff-Hausser counting chamber (Fisher Scientific) [33]. The cells
were infected with the spirochete at a multiplicity of infection (MOI)
of 100 (100 leptospires per host cell) for 1, 2, 4, 8 or 12 h [33,34], and
then lysed with 0.05% NaTDC-PBS. The lysates were centrifuged at 350
×g for 5 min (4 °C) to remove cell debris, and the supernatants were
centrifuged at a 10,000 ×g for 30 min (4 °C) to precipitate leptospires.
Using rabbit anti-L. interrogans strain Lai-IgG as the primary
antibody and Alexa-Fluor488-conjugated goat anti-rabbit-IgG
(Abcam), the integrity of leptospireswere observed under a laser confo-
cal microscope (LSM510-Meta, Zeiss, Germany) (495/519 nm excita-
tion/emission wavelengths for Alexa-Fluor488 detection) [25], in
432 J.-Q. Fang et al. / EBioMedicine 37 (2018) 428–441which the leptospires from culture in EMJH medium was used as the
control. Total leptospiral RNAs were extracted using a TRIzol® Max™
Bacterial RNA Isolation kit (Invitrogen, USA) plus a gDNA Eraser Kit
(TaKaRa) and then quantified by ultraviolet spectrophotometry.
cDNAs from the RNAs were synthesized using a RTase cDNA Synthesis
Kit (TaKaRa). Using the cDNAs as templates, the vwa-I-mRNA and
vwa-II-mRNA levels were assessed by real-time fluorescence quantita-
tive RT-PCR (qRT-PCR) using a SYBR® Premix Ex-Taq™ Kit (TaKaRa)
in an ABI 7500 Real-Time PCR System (ABI, USA). The primers used
are listed in Table 1. In the qRT-PCR, 16S rRNA gene of the spirochete
was used as the internal referencewhile the spirochetes fromEMJHme-
dium (28 °C) and incubated in 2.5% FCS RPMI-1640 medium (37 °C)
were used as the controls. The qRT-PCR data were analyzed using the
ΔΔCt model and randomization test in REST 2005 software [20,34].
2.22. Detection of Lep-vWA-I and Lep-vWA-II expression and secretion of
L. interrogans during infection of HUVEC
HUVECwas infectedwith L. interrogans strain Lai as described above.
The co-cultures were lysed and then centrifuged as above to separate
supernatants and leptospires. Subsequently, the integrity of leptospires
from the co-cultures after lysis were detected by confocalmicroscopy as
described above. The total proteins in the supernatants were extracted
by trichloroacetic acid-acetone precipitation method [24], while the
total leptospiral proteins were extracted by ultrasonical breakage and
centrifugation as above, followed by detection of protein concentration
as above. Using rabbit rLep-vWA-I-IgG or rLep-vWA-II-IgG as the pri-
mary antibody and HRP-conjugated goat anti-rabbit-IgG (Abcam) as
the secondary antibody, Western Blot assay was used to detect Lep-
vWA-I and Lep-vWA-II in the two protein specimens. The immunoblot-
ting signals were quantified for analysis by densitometry (gray scale de-
termination) using an image analyzer (Bio-Rad, USA) [33]. In the assays,
LipL41 or Sph2 and FliY, a stable transmembrane lipoprotein or a se-
creted hemolysin and cytosolic protein of L. interrogans, were used as
the expression or secretion controls [20].
2.23. Secretion inhibition test
L. interrogans strain Lai was pre-treated with 0.1 mM PAβN, a T1SS
inhibitor, 2.5 mM NaN3 and 30 mM NaSCN, the T2SS inhibitors, or
10 mM Aurodox (Sigma), a T3SS inhibitor, for 6 h at 37 °C [35]. The se-
cretion of Lep-vWA-I and Lep-vWA-II of the spirochete during infection
of HUVEC cells was detected by Western Blot assay as above.
2.24. Detection of rLep-vWA-I- or rLep-vWA-II-induced hemorrhage in
mice
Each of C3H/HeJ or C57BL/6 mice was intravenously injected with
100 μg rLep-vWA-I or rLep-vWA-II in 0.1 mL autoclaved PBS and eight
animals were used per group. The animal lung, liver and kidney tissues
aswell as the peripheral blood plasma sampleswere collected on days 3
and 7 after injection for histopathological examination after HE-staining
as well as for detection of prothrombin time (PT), thrombin time (TT),
activated partial thromboplastin time (APTT), thrombin generation
time (TGT), fibrinogen (F\\I) and fibrin degradation product (D-
dimer) concentrations using an Auto-Blood Coagulation Analyzer
(Sysmex, Japan) [16,36]. In addition, the coagulation time (CT) using
Lee-White method, prothrombin (F-II) and prothrombin fragments 1
+ 2 (F1 + 2) concentrations using ELISA, and thrombin generation
time (TGT) using a Hemostasis System Analyzer (Haemoscope, USA)
of the blood plasma samples were also detected as previously described
[16]. On the other hand, the same concentration of rLep-vWA-I or rLep-
vWA-II were pre-incubatedwith rLep-vWA-I-IgG or rLep-vWA-II-IgG at
37 for 1 h and then intravenously injected into the mice for histopatho-
logical examination as above. In the detection, the mice injected with
the same volume of autoclaved PBS were used as the control.2.25. Statistical analysis
Data from aminimumof three independent experimentswere aver-
aged and presented asmean± standard deviation (SD). One-way anal-
ysis of variance (ANOVA) followed by Dunnett's multiple comparisons
test were used to determine significant differences. Statistical signifi-
cance was defined as p b .05.
3. Results
3.1. Extensive distribution of vwa-I and vwa-II genes in pathogenic
Leptospira genospecies
The PCR and sequencing data revealed that all the 13 tested strains
of pathogenic of L. interrogans, L. borgpetersenii or L. weilii but not the
2 tested strains of saprophytic L. biflexa, possess both the LB054
(vwa\\I) and LB055 (vwa-II) genes (Fig. 1A) with the nucleotide or
amino acid sequence identities of 98.9%–99.8% or 98.9%–100% and
98.7%–99.9% or 98.0%–100% (GenBank accession No.: MG744315-
MG744327 and MG744328-MG744340) compared to the reported
same genes (GenBank accession No.: NC_004342.2). Moreover, the
vwa-I or vwa-II genes of L. interrogans strain Lai had higher amino acid
sequence identities (85.6%–100% or 74.4%–100%) compared to those
from all the 13 strains belonging to 9 serogropus and 10 serovars of 5
pathogenic Leptospira genospecies in GenBank (Table 2). Bioinformatic
analysis indicated that the vwa-I and vwa-II genes contain vWF-A su-
perfamily domains (Fig. 1B). Although PsortB software predicted that
the product of vwa-I gene was located in cytoplasmic membrane and
the position of vwa-II gene product was unknown, TMHMM software
predicted the two products as exoproteins without signal peptide se-
quences and transmembrane regionswhile Octopus software presented
the similar possibility of the two products located the inside or outside
of leptospiral cells (Supplementary Fig. S1). The data suggested that
vwa-I and vwa-II genes are required by pathogenic but not non-
pathogenic saprophytic Leptospira strains.
3.2. Characterization of recombinant expression products of vwa-I and
vwa-II genes
The generated prokaryotic expression systems could express the tar-
get recombinant proteins (rLep-vWA-I and rLep-vWA-II) encoded by
the wild-type or point-mutated vwa-I and vwa-II genes of
L. interrogans strain Lai (Supplementary Fig. S2A and S4B). The spectro-
photometric limulus amebocyte lysate test showed that no lipopolysac-
charide (LPS) was detectable in all the rLep-vWA-I and rLep-vWA-II
extracts after endotoxin-removing treatment (Supplementary Fig. S2C
and S4D).
3.3. Hu-Platelet- and GPIbα-binding ability of rLep-vWA-I and rLep-vWA-II
The flow cytometric examination confirmed that both the rLep-
vWA-I and rLep-vWA-II rapidly combined with Hu-platelets with the
94.7% and 92.4% maximal human (Hu)-platelet-binding percentages
(Fig. 2A and Table 3). When the Hu-platelets were blocked with rHu-
GPIbα-IgG, as well as the rLep-vWA-I or rLep-vWA-II was blocked
with rLep-vWA-I-IgG or rLep-vWA-II-IgG, the Hu-platelet-binding abil-
ity of rLep-vWA-I or rLep-vWA-II was absent (Fig. 2A and Table 3). The
surface plasmon resonance (SPR) and isothermal titration calorimetric
(ITC) detection, the two sensitive and reliable methods to determine
protein-protein binding [29,30], revealed that the equilibrium associa-
tion constant (KD) values reflecting the binding ability of rLep-vWA-I
or rLep-vWA-II with rHu-GPIbα were 5.56 × 10−8 and 3.87 × 10−7 M
or 8.65 × 10−8 and 6.42 × 10−7 M (Fig. 2B and C). In particular, the
co-precipitation test showed that the rHu-GPIbα captured five protein
bands from total proteins of L. interrogans strain Lai (Fig. 2D), and the
LC-MS/MS identified two of the captured proteins (~36 kDa) as the
Fig. 1.Distribution and domains of LB054 and LB055 genes in leptospiral strains. (A). The PCR products of leptospiral LB054 (vwa-I) and LB055 (vwa-II) genes, determined by PCR. LaneM:
DNA marker. Lanes 1–13: amplicoms of the vwa-I or vwa-II genes from thirteen pathogenic strains belonging to L. interrogans, L. borgpetersenii or L. weilii. Lanes 14–15: no amplicoms of
vwa-I or vwa-II genes from two saprophytic strains of L. biflexa. (B). Predicted functional domains in LB054 (vwa\\I) and LB055 (vwa-II) genes of L. interrogans strain Lai.
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sequences (LGLVVFAGAAYLQAPLTGDR, SKVIVLITDGVSNTGK
IDPVTATDLAEQIGAK and EDGSYEINFEILQELSANTGGR for vWA-I, and
GLDVDM VGDRGTDLSQAFTK, GTDLSQAFTKAEALLR and
DGTLTSNSNSPGIIHSK for vWA-II) (Supplementary Fig. S3A and 3B).
The other three captured proteins were identified as the products of
LA2066 (~32 kDa, hypothetical protein), LA4255 (~21 kDa, FolE) and
LA2836 (~19 kDa, hypothetical protein) (Supplementary Fig. S3C). The
data suggested that the products of L. interrogans vwa-I and vwa-II
genes have a specific Hu-platelet- or Hu-GPIbα-binding ability.
3.4. Inhibition of rLep-vWA-I and rLep-vWA-II on vWF-mediated platelet
aggregation
Lumiaggregometer is commonly used to detect platelet aggregation
in vitro [26]. Ristocetin, a co-coagulation factor, is necessary for vWF to
induce platelet aggregation in vitro [37]. The platelet aggregation test
showed that rLep-vWA-I and rLep-vWA-II did not cause Hu-platelet ag-
gregation, but could inhibit the rHu-vWF/ristocetin-induced Hu-Table 2
Identity of the amino acid sequences of leptospiral vwa-I/II-like genes.
Genospecies Serogroup Serovar Strain
L. interrogans⁎ Icterohaemorrhagiae Lai Lai
Canicola Canicola Lin
Pyrogenes Pyrogenes Tian
Autumnalis Autumnalis Lin4
Australis Australis 65–9
Pomona Pomona Luo
Grippotyphosa Grippotyphosa Lin6
Hebdomadis Hebdomadis 56,069
L. interrogans⁎⁎ Icterohaemorrhagiae Lai IPAV
Icterohaemorrhagiae Copenhageni Fiocruz L1–
Icterohaemorrhagiae Copenhageni Piscina
Canicola Canicola 114
Pyrogenes Manilae UP-MMC-N
Australis Bratislava PigK151
Grippotyphosa Linhai 56,609
Sejroe Hardjo-prajitno Hardjopraji
L. borgpetersenii⁎ Javanica Javanica M10
Ballum Ballum Pishu
Tarassovi Tarassovi 55–52
Mini Mini Nan10
L. borgpetersenii⁎⁎ Ballum Ballum 56,604
Sejroe Hardjo BK-6
L. weilii⁎ Manhao Manhao 2 L105
L. santarosai⁎⁎ / Shermani LT 821
L. alstonii⁎⁎ / / GWTS #1
L. mayottensis⁎⁎ / / MDI272
⁎ The sequences from the present study by PCR and sequencing.
⁎⁎ The sequences from GenBank.
⁎⁎⁎ The amino acid sequence identity from LB_054 (vwa\\I) and LB_055 (vwa-II) genes in Genplatelet aggregation (Fig. 3A). However, the inhibition of rLep-vWA-I
or rLep-vWA-II could be removed by rLep-vWA-I-IgG or rLep-vWA-II-
IgG pre-blockage (Fig. 3B). Moreover, no phosphorylation of the AKT,
ERK, PLC and PKC as well as no increase of the NO, cGMP, TXA2, free
Ca2+ and ADP levels in the rLep-vWA-I- or rLep-vWA-II-binding Hu-
platelets could be found (Fig. 3C and D). The data suggested that the
products of L. interrogans vwa-I and vwa-II genes can not induce
human platelet aggregation but block the vWF-mediated platelet
aggregation.
3.5. GPIbα-binding sites in Lep-vWA-I and Lep-vWA-II
Previous studies reported that the point-mutation of some certain
amino acid residuals in the region-A of human vWF caused the decrease
of vWF-platelet binding and attenuation of vWF-mediated platelet ag-
gregation [31,32]. The flow cytometric examination revealed that the
recombinant single point-mutated products of L. interrogans vwa-I and
vwa-II genes, rLep-vWA-I-G13S, rLep-vWA-I-R36Q, rLep-vWA-I-G47S,
rLep-vWA-II-G76S and rLep-vWA-II-Q126R but not rLep-vWA-I-Genes GenBank No. Sequence Identity (%)
vwa-I/vwa-II MG744315/744328 100/100⁎⁎⁎
vwa-I/vwa-II MG744316/744329 99.7/99.0
vwa-I/vwa-II MG744317/744330 100/99.0
vwa-I/vwa-II MG744318/744331 99.7/99.7
vwa-I/vwa-II MG744319/744332 100/99.7
vwa-I/vwa-II MG744320/744333 99.7/98.0
vwa-I/vwa-II MG744321/744334 99.0/98.7
vwa-I/vwa-II MG744322/744335 99.7/99.0
RS18585/18590 NC_017552.1 100/100
130 RS18185/18190 NC_005824.1 100/99.4
RS19075/19080 NZ_CP018147.1 99.0/99.4
19,360/19365 CP022884.1 99.7/98.4
IID RS17985/17990 NZ_CP011932.1 99.7/99.7
RS18650/18655 NZ_CP011411.1 100/99.4
RS18625/18630 NZ_CP006724.1 99.7/98.4
tno RS18285/18290 NZ_CP013148.1 100/99.7
vwa-I/vwa-II MG744323/744336 99.3/100
vwa-I/vwa-II MG744324/744337 99.7/100
vwa-I/vwa-II MG744325/744338 99.7/99.7
vwa-I/vwa-II MG744326/744339 99.7/100
RS16395/16400 NZ_CP012030.1 86.2/76.7
RS16740/16745 NZ_CP015045.1 85.6/74.4
vwa-I/vwa-II MG744327/744340 100/99.3
RS17415/17420 NZ_CP006695.1 87.8/73.5
RS19530/19535 NZ_CP015218.1 83.0/66.9
19,315/19320 CP030148.1 87.5/75.8
Bank (NC_004343.2).
Fig. 2. Platelet- and GPIbα-binding ability of rLep-vWA-I and rLep-vWA-II. (A). Hu-platelet-binding ability of rLep-vWA-I and rLep-vWA-II, determined by flow cytometry. rHu-vWF and
rHlpA, a commercial recombinant human vWF and a recombinant hemolysin of L. interrrogans, were used as the controls. (B). rHu-GPIbα-binding ability of rLep-vWA-I and rLep-vWA-II,
determined by SPR. rHlpA, a recombinant hemolysin of L. interrrogans, was used as the control. (C). rHu-GPIbα-binding ability of rLep-vWA-I and rLep-vWA-II, determined by ITC. The
legend is the same as shown in C. (D). rHu-GPIbα-captured leptospiral proteins, determined by co-precipitation test. Lane M: protein marker. Lane 1: total proteins from L. interrogans
strain Lai. Lane 2: proteins released from protein-A-GPIbα-IgG beads. Lane 3: rHu-GPIbα control.
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Table 3
Hu-platelet-binding percentages of rLep-vWA-I and rLep-vWA-IIΔ.
Group (n= 3) Platelet-binding percentage (%, 104 platelets)
0.5 h 1 h 2 h 4 h
rLep-vWA-I 89.9 ± 3.6 90.7 ± 3.8 94.7 ± 4.2 93.3 ± 5.6
rLep-vWA-II 88.2 ± 3.1 90.2 ± 2.9 92.4 ± 3.5 90.7 ± 2.8
rHu-vWF 93.7 ± 3.5 94.4 ± 2.5 95.2 ± 2.1 93.5 ± 2.9
rHu-GP1bα-IgG-blocked rLep-vWA-I 3.5 ± 0.5⁎ 3.7 ± 0.4⁎ 4.2 ± 0.4⁎ 5.4 ± 0.5⁎
rHu-GP1bα-IgG-blocked rLep-vWA-II 3.9 ± 0.5⁎ 4.2 ± 0.6⁎ 4.4 ± 0.6⁎ 5.5 ± 0.5⁎
rHu-GP1bα-IgG-blocked rHu-vWF 2.5 ± 0.1⁎ 2.7 ± 0.1⁎ 3.0 ± 0.2⁎ 3.1 ± 0.2⁎
rLep-vWA-I-IgG-blocked rLep-vWA-I 1.5 ± 0.1⁎ 1.7 ± 0.1⁎ 1.9 ± 0.1⁎ 2.0 ± 0.2⁎
rLep-vWA-II-IgG-blocked rLep-vWA-II 1.7 ± 0.1⁎ 1.8 ± 0.1⁎ 2.0 ± 0.1⁎ 2.1 ± 0.2⁎
rHu-vWFIgG-blocked rHu-vWF 1.4 ± 0.1⁎ 1.7 ± 0.1⁎ 2.1 ± 0.2⁎ 3.9 ± 0.2⁎
Δ The data from experiments such as shown in the Fig. 2A.
⁎ p b .05 vs the Hu-platelet-binding percentages of specific IgG-unclocked rLep-vWA-I, rLep-vWA-II or rHu-vWF.
435J.-Q. Fang et al. / EBioMedicine 37 (2018) 428–441T112A, rLep-vWA-II-G48S and rLep-vWA-II-V75D, presented a signifi-
cant decrease of Hu-platelet-binding and rHu-vWF/ristocetin-induced
Hu-platelet aggregation-inhibiting abilities, compared to the prototypes
of rLep-vWA-I and rLep-vWA-II (Fig. 4). In addition, the multiple point-
mutated rLep-vWA-I-G13S/R36Q/G47S and rLep-vWA-II-G76S/Q126R
could not bind to Hu-platelets and inhibit rHu-vWF/ristocetin-induced
Hu-platelet aggregation (Fig. 4). The SPR and ITC detection also con-
firmed the significant attenuation of rHu-GPIbα-binding ability of the
five single point-mutated rLep-vWA-I or rLep-vWA-II proteins and ab-
sence of rHu-GPIbα-binding ability of the two multiple point-mutated
rLep-vWA-I or rLep-vWA-II protein (Supplementary Fig. S5). The data
suggested that the G13/R36/G47 in Lep-vWA-I and G76/126R in Lep-
vWA-II act as human platelet GPIbα-binding sites.Fig. 3. Inhibition of rLep-vWA-I and rLep-vWA-II on vWF-mediated Hu-platelet aggregation
aggregation, determined by platelet aggregation test. (B). Reversed inhibition of rLep-vWA-I
induced Hu-platelet aggregation, determined by platelet aggregation test. (C). No phosphoryl
determined by Western Blot assay. Lane 1: normal Hu-platelets. Lane 2: vWF/ristocetin-treate
increase of the NO, cGMP, TXA2, free ADP and Ca2+ levels in rLep-vWA-I- or rLep-vWA-II-trea3.6. Increase of expression and secretion of Lep-vWA-I and Lep-vWA-II dur-
ing infection
The cofocal microscopic examination confirmed the integrity of
leptospires from the lysates of Leptospira-cell co-cultures (Fig. 5A).
The qRT-PCR and Western Blot assay showed that the Lep-vWA-I
or Lep-vWA-II mRNA level and protein expression of L. interrogans
strain Lai were significantly increased during infection of human
umbilical vein endothelial cells (HUVEC) (Fig. 5B and C). In particu-
lar, the secretion of Lep-vWA-I and Lep-vWA-II was also observed
during infection (Fig. 5D). The Aurodox, a type 3 secretion system
(T3SS) inhibitor, but not the T1SS and T2SS inhibitors (PAβN,
NaN3 and NASCN) [38], caused a significant decrease in Lep-vWA-. (A). Inhibition of rLep-vWA-I and rLep-vWA-II on vWF/ristocetin-induced Hu-platelet
-IgG and rLep-vWA-II-IgG on rLep-vWA-I and rLep-vWA-II blockage of vWF/ristocetin-
ation of the AKT, ERK, PLC and PKC in rLep-vWA-I- or rLep-vWA-II-treated Hu-platelets,
d Hu-platelets. Lanes 3 and 4: rLep-vWA-I- or rLep-vWA-II-treated Hu-platelets. (D). No
ted Hu-platelets, determined by spectrophotometry and confocal microscopy.
Fig. 4.GPIbα-binding sites in products of vwa-I528 and vwa-II603mutants. (A). Decreased inhibition of point-mutated rLep-vWA-I and rLep-vWA-II on vWF/ristocetin-induced Hu-plate-
let aggregation, determined by platelet aggregation test. (B). Decreased Hu-platelet-binding ability of point-mutated rLep-vWA-I and rLep-vWA-II, determined by flow cytometry. (C).
Statistical summary of the Hu-platelet-binding percentages of point-mutated rLep-vWA-I and rLep-vWA-II. Statistical data from experiments such as shown in B. Bars show the means
± SD of three independent experiments. *: p b .05 vs the Hu-platelet-binding percentages of prototypic rLep-vWA-I or rLep-vWA-II. #: p b .05 vs the Hu-platelet-binding percentages
of single point-mutated rLep-vWA-I or rLep-vWA-II.
436 J.-Q. Fang et al. / EBioMedicine 37 (2018) 428–441I and Lep-vWA-II secretion (Fig. 5E). The data suggested that vwa-I
and vwa-II genes are required by L. interrogans during infection and
the vwa-I and vwa-II gene products can be secreted through lepto-
spiral T3SS.3.7. Hemorrhage induced by rLep-vWA-I and rLep-vWA-II in mice
The gross pathological examination showed that all the lungs of
rLep-vWA-I- or rLep-vWA-II-injectedmice presented visible hyperemia
Fig. 5. Increase of vwa-I and vwa-II gene expression and secretion during infection. (A) The integrity of leptospires from the lysates of Leptospira-cell co-cultures, examined by cofocal
microscopy. (B) Increase of vwa-I- or vwa-II-mRNA levels in L. interrogans strain Lai during infection of HUVEC, determined by qRT-PCR. Bars show the mean± SD of three independent
experiments. The vwa-I- or vwa-II-mRNA levels in the spirochete from EMJH medium (before infection) were set as 1.0. *: p b .05 vs the vwa-I- or vwa-II-mRNA levels in the spirochete
before infection or in incubationwith RPMI-1640medium at 37 °C. (C). Increase of Lep-vWA-I and Lep-vWA-II expression in L. interrogans strain Lai during infection of HUVEC, determined
byWestern Blot assay. LipL41, a leptospiral outer membrane lipoprotein, was used as the control. The immunoblotting bands reflecting Lep-vWA-I and Lep-vWA-II expression levels dur-
ing infection were quantified by gray scales. Bars show the mean ± SD of three independent experiments. The gray scale values of immunoblotting bands from the spirochete in EMJH
medium (before infection)were set as 1.0. *: p b .05 vs the gray scale values reflecting the expression levels of Lep-vWA-I and Lep-vWA-II of the spirochete before infection. (D). Secretion
of Lep-vWA-I and Lep-vWA-II of L. interrogans strain Lai during infection of HUVEC, determined byWestern Blot assay. Sph2, a secreted leptospiral hemolysin, and FliY, a leptospiral cy-
tosolic protein, were used as the controls. The rest of legend is the same as in B but for detection of Lep-vWA-I and Lep-vWA-II secretion. *: p b .05 vs the gray scale values reflecting the
secreted Lep-vWA-I and Lep-vWA-II levels of the spirochete before infection. (E). Lep-vWA-I and Lep-vWA-II secretion through T3SS during infection of HUVEC, determined byWestern
Blot assay. PAβN or Aurodox is the T1SS or T3SS inhibitor while NaN3 and NaSCN are T2SS inhibitors. The rest of legend is the same as in B but for determination of Lep-vWA-I and Lep-
vWA-II secretion pathways. *: p b .05 vs the gray scale values reflecting the secreted Lep-vWA-I and Lep-vWA-II levels of the spirochete before infection.
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pared to those of normal mice (Fig. 6A). The pathological examination
showed that both rLep-vWA-I and rLep-vWA-II caused the pulmonarydiffuse hemorrhage with interstitial pneumonia and extensive renal
focal hemorrhage (Fig. 6B and C). When rLep-vWA-I or rLep-vWA-II
was pre-blocked by rLep-vWA-I-IgG or rLep-vWA-II-IgG, the
Fig. 6. rLep-vWA-I- and rLep-vWA-II-induced hemorrhage in mice. (A). The gross pathological changes of lungs, livers and kidneys of rLep-vWA-I- or rLep-vWA-II-injected C3H/HeJ or
C57BL/6 mice. (B). rLep-vWA-I- or rLep-vWA-II-induced hemorrhage in C3H/HeJ mice, observed by microscopy after HE-staining. (C). rLep-vWA-I- or rLep-vWA-II-induced
hemorrhage in C57BL/6 mice, observed by microscopy after HE-staining.
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absent (Supplementary Fig. S6). The data suggested that the products of
L. interrogans vwa-I and vwa-II genes act as hemorrhage inducers in
mice.
3.8. Ms-platelet-binding ability of rLep-vWA-I and blood coagulation
dysfunction
The flow cytometric examination confirmed that rLep-vWA-I and
rLep-vWA-II could rapidly bind to Ms-platelets form C3H/HeJ or
C57BL/6 mice with the 91.9% and 90.5% or 92.1% and 91.6% maximal
human (Hu)-platelet-binding percentages (Fig. 7A and B). On the
other hand, the coagulation time (CT), prothrombin time (PT), throm-
bin time (TT), activated partial thromboplastin time (APTT) and throm-
bin generation time (TGT) of peripheral blood specimens from the two
rLep-vWA-I- or rLep-vWA-II-injected mice presented a 2.36–8.81 fold
extension but the fibrinogen (coagulation factor I, F\\I), prothrombin
(coagulation factor II, F-II), prothrombin degradation fragments (F1+2) and fibrin degradation product (D-dimer) levels had no significant
changes, compared to the normal mice (Fig. 7C). The data suggested
that the products of L. interrogans vwa-I and vwa-II induce hemorrhage
in mice due to attenuation or dysfunction of platelet aggregation.
4. Discussion
Leptospira is a large group of Gram-negative helical prokaryotic mi-
crobes that can be classified into pathogenic and non-pathogenic sapro-
phytic Leptospira genospecies [1,2,11]. Both the pathogenic and
saprophytic Leptospira genospecies express surface LPS (i.e. endotoxin)
[39], but only the former is pathogenic due to expression of many inva-
sive and virulence factors such as the ColA collagenase, the LigB
adhensin, the Mce invasive protein and the OMP047 apoptotic inducer
[20,25,34,40]. Unlike saprophytic Leptospira, which live in the natural
environment, pathogenic Leptospira need to invade into animal hosts
for propagation. This requires certain genetic diversity between the sap-
rophytic and pathogenic Leptospira genospecies. In the present study,
Fig. 7.Ms-platelet-binding ability of rLep-vWA-I and blood coagulation dysfunction. (A). Ms-platelet-binding ability of rLep-vWA-I and rLep-vWA-II, determined by flow cytometry. rHu-
vWF, a commercial recombinantmouse vWF,wasused as the control. (B). Statistical summary of theMs-platelet-binding percentages of rLep-vWA-I and rLep-vWA-II. Statistical data from
experiments such as shown in A. Bars show themeans± SD of three independent experiments. *: p b .05 vs the normalMs-platelets. (C). Extension of the CT, PT, TT, APTT and TGT aswell
as no change of the F\\I, D-dimer, F-II and F1+ 2 levels of peripheral blood specimens from rLep-vWA-I- or rLep-vWA-II-injected mice, determined by using an Auto-Blood Coagulation
Analyzer and ELISA. *: p b .05 vs the CT, PT, TT, APTT and TGT of peripheral blood specimens from normal mice.
439J.-Q. Fang et al. / EBioMedicine 37 (2018) 428–441we found that only the strains from pathogenic Leptospira, but not from
saprophytic Leptospira genospecies, possess sequence-conserved vwa-I
and vwa-II genes. In particular, the expression of L. interrogans vwa-I
and vwa-II genes as well as the secretion of their products (Lep-vWA-I
and Lep-vWA-II) were observed during infection of human vascular en-
dothelial cells. However, the T3SS inhibitor (Aurodox) but not the T1SS
and T2SS inhibitors could inhibit the secretion of Lep-vWA-I and Lep-vWA-II. Earlier studies reported that L. interrogansmay possess an in-
complete type III secretion system (T3SS) because no genes could be
predicted to encode a transmembrane channel in the T3SS for transport
of proteins [41,42]. However, a recent study showed that the product of
the gspD gene in L. interrogans strain Lai was predicted as a YscC-like
protein, a porin for protein secretion in T3SS of Yersinia pestis [43]. Our
data indicate that the pathogenic but not saprophytic Leptospira
440 J.-Q. Fang et al. / EBioMedicine 37 (2018) 428–441genospecies possess vwa-I and vwa-II genes and the products of vwa-I
and vwa-II genes can secrete through T3SS during infection.
Many prokaryotic pathogens, such as Escherichia coli, Shigella
dysenteriae, Helicobacter pylori, Clostridium difficile and Rickettsia spe-
cies, can cause hemorrhagic injury of infected hosts [44–48]. LPS has
been confirmed as a strong causative agent of hemorrhage due to the
inflammation-mediated increase of vascular permeability, damage of
vascular endothelial cells and basement membrane, and inhibition of
platelet adhesion and aggregation [49–51]. However, the biological ac-
tivity of leptospiral LPS ismuch lower than that of E. coli LPS,while hem-
orrhage in leptospirosis is much more severe [6,13,25,39]. Therefore,
pathogenic Leptospira genospecies must produce some factors other
than leptospiral LPS in order to induce hemorrhage during infection.
GPIb is a platelet transmembrane protein composed of two α-
subunits and two β-subunits [52]. During the process of vWF-induced
platelet aggregation in vivo, vWF first binds to platelets through its
vWF-A domain with the leucine-rich repeat N-terminal (LRRNT) do-
main of GPIbα to form a vWF-GPIb-IX-V complex that further initiates
PI3K/AKT-PLC/PKC signaling to cause talin/integrin-dependent platelet
aggregation [19,28]. Therefore, the GPIbα-binding ability of rLep-
vWA-I and rLep-vWA-II, the products of L. interrogans vwa-I and vwa-
II containing vWF-A superfamily domains, is the key feature of these
two proteins for their ability to induce hemorrhage by competitive
blockage of vWF. In the present study, both rLep-vWA-I and rLep-
vWA-II were able to interact with Hu-platelets but also bind to rHu-
GPIbα with KD values of 3.87 × 10−7-8.65 × 10−8 M. KD values lower
than 10−6 M generally indicate high-affinity protein-protein interac-
tions [29,30]. In particular, latelet aggregation and aggregation inhibi-
tion tests confirmed that rLep-vWA-I and rLep-vWA-II blocked rHu-
vWF/ristocetin-induced Hu-platelet aggregation in vitro. Moreover,
this study also identified G13, G47 and R36 in Lep-vWA-I and G76 and
Q126 in Lep-vWA-II as the rHu-GPIbα-binding residues. All the data
demonstrate that the L. interrogan vwa-I and vwa-II gene products ex-
hibit human platelet GPIbα-biding ability and can cause hemorrhage
during leptospirosis by competitive inhibition of vWF-mediated platelet
aggregation.
Hemorrhage can be classified as disruptive hemorrhage due to ves-
sel wall injury and diapedetic hemorrhage due to thrombocytopenia
and platelet dysfunction and is usually caused by heredopathia, malnu-
trition, leukemia or microbial infections [16,53]. Younger guinea pigs
and Syrian hamsters are more suitable for leptospirosis animal models
[54,55], but C3H/HeJ and C57BL/6 mice are also commonly used as the
experimental hosts of L. interrogans [56,57]. In particular, commercial
experimental reagents for mice but not for guinea pigs and Syrian ham-
sters are readily available. Animal experiments in our study showed that
100 μg rLep-vWA-I or rLep-vWA-II was able to cause severe diffuse
diapedetic hemorrhage in lung tissues and extensive focal diapedetic
hemorrhage in kidney tissues of mice, while hemorrhage could be
blocked by rLep-vWA-I or rLep-vWA-II-IgG. CT, TT, PT, APTT and TGT
are common assays to assess coagulation function of blood as well as
the prothrombin degradation fragments (F1 + 2) and fibrin degrada-
tion product (D-dimer) levels reflect the generation of thrombin from
activated prothrombin and formation of fibrin from cleaved fibrinogen
[16,36]. Compared to the normal mice, all the coagulation times of pe-
ripheral blood specimens from rLep-vWA-I- and rLep-vWA-II-injected
micewere extended, but no changes of thefibrinogen (F\\I), prothrom-
bin (F-II), F1+2 andD-dimer levelswere found. In the process of blood
coagulation, the aggregated platelets induced by vWF can produce co-
agulation factor V and combinewith coagulation factor X to form a com-
plex that cleaves prothrombin into thrombin to cause the conversion of
fibrinogen into fibrin [17,58,59]. Moreover, the rLep-vWA-I- or rLep-
vWA-II-injected mice also presented interstitial pneumonia. Previous
studies revealed that heme, heat shock protein-60 (HSP60) and adeno-
sine 5′ triphosphate released from erythrocytes can induce inflamma-
tion through NLRP3 inflammasome, NF-κB and Ca2+/PKC signaling
pathways of macrophages and vascular endothelial cells [60–62].Therefore, the interstitial pneumonia observed in the mice may be
caused by the released components of erythrocytes. All the data indicate
that the products of L. interrogan vwa-I and vwa-II genes can cause hem-
orrhage in mice probably due to dysfunction and disorder of platelet
aggregation.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2018.10.033.
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